Increase of hepcidin plasma and urine levels is associated with acute proctitis and changes in hemoglobin levels in primary radiotherapy for prostate cancer
- First Online:
- 142 Downloads
To analyse hepcidin serum and urine levels during radiotherapy for prostate cancer.
In 18 patients undergoing radiotherapy for prostate cancer, blood, plasma, and urine samples were taken before and during radiotherapy. Complete blood cell count, pro-hepcidin-, ferritin-, transferrin-, IL-1β-, IL-6-, and TNF-α concentration was determined. Pro-hepcidin concentration was additionally measured in urine samples. Toxicity was evaluated weekly. Differences among tested factors were tested by Wilcoxon rank sign test for paired data.
In ten patients developing acute radiation-induced proctitis, a significant increase in pro-hepcidin, IL-6, and TNF-α plasma levels (p < 0.05) was detected. Pro-hepcidin urine levels also showed a strong trend towards increase (p = 0.06). Concurrently, hemoglobin, and leucocytes were significantly decreased in the patients with acute proctitis (p < 0.05). In eight patients showing no symptoms of proctitis, solely a significant decrease for leucocytes was detected. Additive, these patients showed a significant increase of ferritin, and a decrease of transferrin levels (p < 0.05).
Hepcidin levels are increased and hemoglobin is decreased during radiotherapy for prostate cancer in patients who develop acute proctitis. Radiation-induced expression of cytokines may be responsible for increased hepcidin expression in the liver. Regulation of iron metabolism by hepcidin may be an underestimated response in radiotherapy.
KeywordsHepcidin Radiotherapy Prostate cancer Proctitis Cytokines
- Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF, Carrie C (2005) Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol 23:8748–8756PubMedCrossRefGoogle Scholar
- Christiansen H, Sheikh N, Saile B, Reuter F, Rave-Frank M, Hermann RM, Dudas J, Hille A, Hess CF, Ramadori G (2006) X-radiation leads to up-regulation of hepcidin and down-regulation of hemojuvelin and ferroportin-1 gene expression in rat liver. Radiology (in press)Google Scholar
- International Commission on Radiation Units and Measurements (1993) Prescribing, recording and reporting photon beam therapy. ICRU Report No. 50, MP, BethesdaGoogle Scholar
- Lipinski P, Starzynski R (2004) Regulation of body iron homeostasis by hepcidin. Postepy Hig Med Dosw 58:65–73Google Scholar
- Lipman AJ, Lawrence DP (2004) The management of fatigue in cancer patients. Oncology (Williston Park) 18:1527–1535Google Scholar
- Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD (2000) Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46:391–402PubMedCrossRefGoogle Scholar
- Ozsahin M, Azria D, Beer K, Mirimanoff RO, Zouhair A (2005) External radiotherapy and anaemia treatment: state of the art. Swiss Med Weekly 135:4–10Google Scholar
- Sobin LH, Wittekind C (1997) TNM classification of malignant tumours, 5th edn. Wiley/Liss, New YorkGoogle Scholar
- Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0 an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13–47PubMedCrossRefGoogle Scholar